Subtypes of Triple-negative Breast Cancer Cell Lines React Differently to Eribulin Mesylate.

201612 citationsJournal Article

Authors

Karen Bräutigam · Universitäres Kinderwunschzentrum Lübeck

Katharina Mitzlaff · University Hospital Schleswig-Holstein

Lisa Uebel · University Hospital Schleswig-Holstein

Frank Köster · University Hospital Schleswig-Holstein

Stephan Polack · University Hospital Schleswig-Holstein

Mascha Pervan · University Hospital Schleswig-Holstein

Gunnar Steinert

Abstract

Eribulin had a strong antiproliferative effect on breast cancer cell lines, although we did not observe a significant difference between TNBC and non-TNBC cell lines with regard to sensitivity to eribulin.

Topics & Keywords

Cancer Treatment and Pharmacology HER2/EGFR in Cancer Research Cancer-related Molecular Pathways

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: PubMed

Volume 36, Issue 6, pp. 2759-66

Field-Weighted Citation Impact: 0.46